Delving into the Latest Updates on Mumps Vaccine, Live(Wuhan Institute of Biological Products Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Live attenuated vaccine, Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Mouth and Tooth Diseases

Active Indication

Parotitis

Inactive Indication-

Originator Organization

Wuhan Institute of Biological Products Co., Ltd.

Active Organization

Wuhan Institute of Biological Products Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1994),

Parotitis

Regulation-

Login to view timeline

Live mumps vaccine was added to clinic and school immunization programs in 1968. Requests for clinic immunization were highest among children under 10 years of age and lowest among adults. In the school program, 13% of the fourth grade enrollment (37% of estimated susceptibles) requested vaccine while only 2% of 12th grade enrollment (10% of estimated susceptibles) requested vaccine. Motivation of adults and older teen-agers to seek immunization for themselves is probably so low that this approach will not significantly reduce the incidence of adult mumps. Immunization of children under 10 years is very acceptable to the public. Since over three fourths of all mumps cases occur in children under age 10, their protection through immunization should bring the added benefit of reducing the incidence of mumps in adults by reducing exposure of adults to children with mumps.

100 Deals associated with Mumps Vaccine, Live(Wuhan Institute of Biological Products Co., Ltd.)

Login to view more data